SONM enters its Q4 2025 earnings call on Monday, May 18 carrying the most turbulent short-interest week of its recent history — and an unanswered question about whether it can file its quarterly report on time.
The short-side story this week has been genuinely chaotic. Short interest more than doubled in five sessions, surging 129% week-on-week to a peak of around 69,000 shares on Monday, May 11. Then it reversed sharply. By Thursday, May 14 it had fallen back to roughly 38,000 shares — a 45% retreat from that intraday peak, leaving SI at about 3.7% of the free float. The pattern reads less like conviction and more like opportunistic positioning around near-term uncertainty, with shorts piling in and then quickly covering as the stock continued to slide. The shares closed Friday at $4.77, down 6% on the week and 6% on the day, though still up more than 42% over the past month — a reminder of how compressed and reactive this micro-cap has been.
The borrow market has loosened somewhat, though conditions remain moderately tight. Cost to borrow has eased from a 30-day high near 11.9% in late April to about 9.5% now. Availability — the ratio of shares still available to lend relative to those already borrowed — is running at roughly 80%, which points to a reasonably accessible lending pool for a stock this small. That's meaningfully looser than the 52-week trough when availability was near fully depleted at under 3% of the borrow pool. The ORTEX short score is 55, a mid-range reading that has slipped from 62 on Monday — consistent with the short covering observed across the week. Days to cover stand at 4.3, meaning any renewed push to re-short would take several sessions to unwind at typical volumes.
The timing of the May 18 earnings call carries a wrinkle. On Friday, DNA X filed an NT 10-Q with the SEC — a formal notice that it cannot file its Q1 2026 quarterly report by the standard deadline. This is the most notable near-term catalyst. NT filings typically signal either accounting complexity, auditor issues, or operational strain. For a company that rebranded from Sonim Technologies, reported a $20.7m annual net loss in FY2025 (improved from $33.6m), and carries a market cap of just $7.1m, investors heading into Monday's call are navigating both the results and the filing delay simultaneously. The stock's last earnings event, in April, saw it fall 5% on the day before recovering 24% over the following five sessions — a pattern that captures how quickly sentiment can flip on a name this thinly traded.
Institutional ownership is heavily concentrated at the top. Laurence Lytton holds nearly 10% of shares, and his latest Schedule 13G/A was filed on Friday — adding a further data point to watch on the ownership side. The top 18 institutional holders collectively account for a meaningful share of the float, meaning position changes from any single holder can move the needle materially. The insider data on file is stale (as of June 2025), so no fresh signal is available from that channel ahead of Monday.
What to watch: whether the company provides any explanation for the NT 10-Q delay on the May 18 call, and whether the short book — which just completed a violent round-trip — re-engages or continues to unwind after the print.
See the live data behind this article on ORTEX.
Open SONM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
